Pharmacogenomics of Antidepressant Response in Children and Adolescents
NCT00516932 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 211
Last updated 2015-04-17
Summary
This study will identify variations in genes that may be involved in the development of suicidal events or certain behaviors in youth who are exposed to antidepressant medications.
Conditions
- Anxiety Disorders
- Depression
- Eating Disorders
- Obsessive-Compulsive Disorder
- Suicide Prevention
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
collaborator NIH - lead OTHER
Principal Investigators
-
John S. March, MD, MPH · Duke University
Eligibility
- Min Age
- 7 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2009-10-31
- Completion
- 2009-10-31
Countries
- United States
Study Locations
More Related Trials
-
Pharmacogenetics Associated With IV Ketamine
NCT04695405 ·Status: COMPLETED
-
Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study
NCT00300820 ·Status: COMPLETED
-
Exome Sequencing in Autistic Spectrum Disorder
NCT01059201 ·Status: COMPLETED
-
Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects
NCT03748355 ·Status: COMPLETED ·Phase: NA
-
Longitudinal Family/Molecular Genetic Study to Validate Research Domain Criteria
NCT02415647 ·Status: COMPLETED
-
Study of the Genetic Factors Involved in Autism and Related Disorders
NCT04727489 ·Status: RECRUITING
-
Genetic Risk: Whether, When, and How to Tell Adolescents
NCT03421327 ·Status: COMPLETED
-
Utility of PharmacoGenomics for Reducing Adverse Drug Effects
NCT02081872 ·Status: UNKNOWN
-
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
NCT01507155 ·Status: COMPLETED ·Phase: NA
-
Genetics of Obsessive-Compulsive Disorder
NCT00001548 ·Status: COMPLETED
-
Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder
NCT03829176 ·Status: COMPLETED ·Phase: NA
-
Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols
NCT01375543 ·Status: COMPLETED
-
Observational Study of Advanced Data Analytics in Genetic Conditions
NCT05657405 ·Status: RECRUITING
-
Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression
NCT05480826 ·Status: RECRUITING ·Phase: NA
-
Genetic Aspects of Neurologic and Psychiatric Disorders
NCT00001544 ·Status: COMPLETED
-
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
NCT05437588 ·Status: RECRUITING ·Phase: NA
-
Study of Clinical and Molecular Manifestations of Genetic Disorders
NCT00001466 ·Status: COMPLETED
-
Genetic Predictors of Lithium Response in Bipolar Disorder
NCT00252577 ·Status: COMPLETED
-
Pharmacogenetic Testing for Medication Management.
NCT02559193 ·Status: WITHDRAWN
-
Genetics and Psychopathology in the 22q11 Deletion Syndrome
NCT00161109 ·Status: UNKNOWN
-
Pharmacogenetic Testing in Primary Care
NCT01600846 ·Status: COMPLETED
-
Pediatric Reporting of Adult-Onset Genomic Results
NCT03832985 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
NCT03468309 ·Status: COMPLETED
-
Genetic Architecture of Avoidant/Restrictive Food Intake Disorder
NCT05605067 ·Status: COMPLETED
-
Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana
NCT04083261 ·Status: COMPLETED